Chemotherapy Market Insights, 2006-2016

Chemotherapy Market Insights, 2006-2016

A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities

This comprehensive report is designed to present a state-of-the-art view of chemotherapy approaches to the treatment of cancer and an assessment of the critical parameters of drug discovery and development that may lead to the introduction of new oncology drugs with great therapeutic and market potential over the next decade. The oncology market is currently the fastest growing in the pharmaceutical industry, driven by the explosion of potential therapeutic targets revealed by the molecular genetic assessments of cancer biology and fuelled by the magnitude of the disease worldwide, which shows every indication of increased incidence and sustained mortality rates over the next decade. Currently, there are 25 million people afflicted with cancer worldwide, and the World Health Organization (WHO) predicts that cancer rates may increase by 50% from 10 million cases in 2000 to 15 million cases in 2015. Moreover, the Association for International Cancer Research (AICR) estimates that by 2020, there will be 10 million deaths from cancer. Even in developed nations, approximately 50% of patients diagnosed with cancer will eventually die of this disease. The challenges are great, but the world of molecular medicine and biopharmaceuticals has presented great opportunities to discover and develop new pharmacological approaches with prospects for greater therapeutic efficacy and more promising clinical outcome.

in this report, Chemotherapy Market Insights, 2006-2016: A Critical Analysis of CancerResearch, Treatments, Pipelines, and Commercial Opportunities, the reader will be presented with an expert perspective on oncology therapeutics, drug development, and commercial opportunities within the field. The introductory chapter is designed to provide a global perspective on the many facets of cancer that will affect the discovery, development and marketing of oncology pharmaceuticals over the next decade. among the critical disease parameters are the global epidemiology of cancer, which includes current incidence, survival and mortality trends for the most common cancers worldwide. This assessment is designed to focus attention on the types of cancer that may be most appropriately targeted for treatment research and development based on these current global statistics.

These statistics also highlight the types of cancer that continue to be most refractory to current treatment approaches, suggesting areas for future research in drug discovery. Each of the many common cancers is assessed in this chapter with respect to its aetiology, pathophysiology, diagnosis, current treatment options, and clinical outcomes.

Objectives of The Report

The objectives of this report are to provide an in-depth assessment and analysis of the global cancer therapy market. Included in this study are critical analyses of key therapeutic areas, epidemiological, aetiological, and healthcare data, pipeline programs, and innovating companies and products. IT is hoped that the reader will benefit from critical review, market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

Contents

• Executive Summary
• Objective of the Report
• Research Methodology
• Chapter 1. Introduction to Cancer: Epidemiology, Pathophysiology, Diagnosis, and Treatment
  • Cancer Epidemiology
  • Global Epidemiology of Cancer
  • Global Statistics (World Health Organization - WHO)
  • Cancer Incidence and Mortality by Geographical Regions Worldwide
  • Cancer Epidemiology, United Kingdom (Office of National Statistics)
  • Cancer Incidence and Mortality
  • United Kingdom: Current Incidence Trends
  • Incidence by Age Group, United Kingdom
  • Current Mortality Trends in the United Kingdom
  • Survival Trends for Most Common Cancers in the United Kingdom
  • Current Cancer Statistics in the United States - American Cancer Society and
  • Surveillance, Epidemiology and End Results Program (SEER)
  • Current Incidence and Mortality Rates for the Most Common Cancers in the United
  • States
  • Current Cancer Estimates in the United States, 2005
  • Incidence and Mortality Rates by Racial Group, United States
  • Aetiology, Pathophysiology, and Diagnosis of Cancer by Type: Europe, United
  • Kingdom and United States
  • Lung Cancer
  • Aetiology of Lung Cancer
  • Risk Factors for Lung Cancer
  • Pathophysiology of Lung Cancer
  • Diagnosis of Lung Cancer
  • Treatment of Lung Cancer
  • Lung Cancer: Outcome
  • Colorectal Cancer
  • Aetiology and Pathophysiology
  • Risk Factors for Colon Cancer
  • Diagnosis of Colon Cancer
  • Treatment of Colon Cancer
  • Colon Cancer: Outcome
  • Breast Cancer
  • Aetiology of Breast Cancer
  • Risk Factors for Breast Cancer
  • Pathophysiology of Breast Cancer
  • Diagnosis of Breast Cancer
  • Treatment of Breast Cancer
  • Breast Cancer: Outcome
  • Prostate Cancer
  • Aetiology of Prostate Cancer
  • Pathophysiology of Prostate Cancer
  • Diagnosis of Prostate Cancer
  • Treatment of Prostate Cancer
  • Prostate Cancer: Outcome
  • Incidence and Mortality Rates for Other Common Cancers: Europe, and
  • North America
  • Cancer Staging and Grading: Diagnostic and Therapeutic Criteria
  • Common Solid Tumour Malignancies
  • Chemotherapy for Leukaemias and Lymphomas: Standard Treatment Options
  • Leukaemias
  • Lymphomas
• Chapter 2. Drug Development Challenges
  • Tumour Biology
  • Important Discoveries in Tumour Biology: Viruses, Genes and Cancer
  • Cancer Genetics
  • towards a Model on the Genetic Origins of Cancer
  • Pharmacology
  • Pharmacology of the Important Groups of Chemotherapeutic Drugs Used in the
  • Treatment of Cancer
  • Mechanism of Action of Major Groups Chemotherapy Drugs and Treatment Applications
  • Antimetabolites
  • Antibiotics
  • Alkylating Agents
  • Vinca Alkaloids
  • Other Alkaloids
  • Platinum Compounds
  • Treatment Resistance
  • General Parameters of Drug Resistance
  • Pharmacological Parameters of Chemosensitivity - Drug Delivery Applications
  • Genetic Components of Drug Resistance Mechanisms
  • Acquired Drug Resistance Mechanisms
  • Current Biological and Pharmacological Obstacles to the Successful Treatment
  • of Cancer
  • Biological Complexity
  • Pharmacological Challenges
  • New Research/Technologies
  • Gene-Targeted Therapeutic Approaches
  • Angiogenesis
  • Apoptosis
  • Application of New Technologies to Chemotherapy Research and Development
• Chapter 3. Chemotherapeutic Treatment Options: Clinical Management and Drug Development Issues
  • Current Chemotherapies
  • Chemotherapy Treatment Overview
  • Treatment Options
  • Clinical Assessment of Solid Tumours
  • Organ-Specific Chemotherapy
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Testicular Cancer
  • Cancers of Haematopoetic Origin - The Leukaemias
  • Leukaemias
  • Hodgkin's Disease
  • Non-Hodgkin's Lymphoma
  • Chemotherapy Drugs Approved by the United States Food and Drug Administration
  • Chemotherapy Side Effects
  • Clinical Treatment Administration Protocols
  • Chemotherapy Drugs and Market Opportunities
  • Chemotherapy Drug Reformulation
  • Novel Drug Delivery Systems
• Chapter 4. The Market for Cancer Chemotherapies
  • The Market for Chemotherapies
  • The Global Cancer Market: Trends, Estimates, Economics, and Outlook
  • Cancer Market: Overview
  • Best-Selling Oncology Products
  • Pharmaceutical Product Growth in Oncology
  • Licensing and Chemotherapy Products
  • Cancer Treatments and Pharmacoeconomics
  • Critical Factors Affecting the High Pricing of Patented Cancer Drugs
  • Generic Erosion
  • High Costs of the New Super Drugs
  • Healthcare Costs: United States
  • Prescription Drug Costs and Coverage
  • Healthcare Reimbursement Issues: United States
  • Local Community Health Services
  • Private Sector Health Programs: Managed Care
  • Healthcare Purchasing Cooperatives: Federal Employers Health Benefits Program
  • Uninsured Americans
  • Current Issues in United States Healthcare Policy
  • Healthcare Policies: United Kingdom
  • National Health Service/National Institute for Health and Clinical Excellence
  • Healthcare Policies: United States versus United Kingdom
  • Healthcare Costs: Europe
  • Future Trends in the Cancer Market Based on Cancer Incidence
  • General Assessment of Future Trends in Cancer Therapeutics
  • Cancer Incidence, Survival and Mortality Rates: General Trends
  • Future Trends Based on Successful Treatment Approaches
  • General Considerations
  • Market Outlook for New Cancer Drugs
  • Current Chemotherapies: Product Review and Commercial Outlook
  • Genentech/Roche: Newly Approved Cancer Drug
  • Avastin
  • Tarceva
  • Rituxan
  • Herceptin
  • Genentech Bio-Oncology Market Data: 2004-2005
  • Roche
  • American Pharmaceutical Partners: Abraxane
  • MGI Pharma/Guildford Pharmaceuticals: Aloxi/Gliadel Wafer
  • Sanofi-Aventis: Taxotere/Eloxatin
  • Pfizer
  • Aromasin
  • Other Drugs in Pfizer's Portfolio
  • AstraZeneca
  • Arimidex
  • Faslodex
  • Zoladex
  • Iressa
  • Novartis
  • Gleevec
  • Zometa
  • Sandostatin
  • Femara
  • Schering-Plough
  • Temodar
  • Intron A
  • GlaxoSmithKline
  • Zofra
  • Hycamtin
  • Bexxar
  • Arranon
  • Genzyme
  • Clolar
  • Thyrogen
  • Imclone: Erbitux
  • 3M Pharmaceuticals: Aldara
  • Supportive Therapies
  • MGI Pharma
  • Other Support Therapies
  • Cancer Market Outlook: Summary
• Chapter 5. Chemotherapies in Research and Development
  • General Trends in Global Oncology Markets Considered to Impact Chemotherapies
  • in Research and Development
  • Important Therapeutic Areas Targeted for Research and Development
  • Promising New Oncology Drugs Poised for Market Entry
  • Therapeutic Clinical Oncology Candidates: Product Review
  • Cancer Vaccines: Gardasil (Merck) and Cervarix (GlaxoSmithKline)
  • Sutent - Pfizer
  • Sorafenib (BAY43-9006) - Bayer/Onyx
  • Panitumamab - Amgen/Abgenix
  • Prospective Oncology Drugs in Research and Development: Challenges for
  • Drug Development
  • Promising Cancer Drugs in Late-Stage Clinical Trials
  • GlaxoSmithKline (GSK): Pipeline Products in Late-Stage Development
  • Tykerb (Lapatinib)
  • Eltrombopag
  • Casopitant
  • Novartis
  • Femara
  • PTKZK
  • Introgen Therapeutics: Advexin
  • United Therapeutics: OvaRex
  • GPC Biotech AG: Satraplatin
  • Cell Therapeutics: Xyotax
  • NeoPharm: LEP-ETU
  • Genta Pharmaceuticals: Genasense
  • SuperGen: Orathecin
  • Dendreon: Provenge
  • Bayer: Sorafenib
  • Promising Oncology Portfolios in Clinical Development
  • GlaxoSmithKline
  • Iboctadekin
  • Vestipitant
  • Ispenesib
  • Pazopanib
  • Relacatib
  • Elacridar
  • Novartis
  • RAD001
  • Patupilone
  • PKC412
  • ST1571
  • Gimatecan
  • AMN107
  • AEE788
  • INGN225
  • INGN241
  • INGN401
  • Eisai
  • Phase-III Products
  • Phase-II Products
  • Phase-I Products
  • Abbott Laboratories
  • Xinlay (Atrasentan)
  • Merck
  • SAHA
  • Promising Biopharmaceutical Oncology Products in Clinical Development
  • Market Outlook for New Oncology Products in Late-Stage Development
• Chapter 6: Cancer Research - Evaluating Drug Development and Market Opportunities
  • Current Themes and Trends in Cancer Research
  • Cancer Therapeutic Approaches in Research and Development
  • Supportive Therapies
  • Stem Cell Therapy
  • Immunotherapy
  • Emerging Biotechnologies
  • Recombinant Vaccines
  • Antisense Technology
  • Humanized Monoclonal Antibodies
  • Gene Therapy
  • Nanoparticle Technology
  • Current Biotechnological Cancer Therapeutic Approaches
  • Therapeutic Cellular Vaccines
  • Antigen/Adjuvant Vaccines
  • Whole Tumour Vaccines
  • Viral Vectors and DNA Vaccines
  • Idiotype Vaccines
  • Dendritophages
  • Molecular Targets of Therapeutic Vaccines
  • Therapeutic Vaccines in Clinical Trials
  • Passive Immunotherapy: Monoclonal Antibodies
  • Therapeutic Classes of Monoclonal Antibodies
  • Anti-CD20 Monoclonal Antibodies
  • Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies
  • Cell Death Targets
  • Small Molecule Targeted Anticancer Agents
  • Promising Small Molecule Therapeutic Targets in Research and Development
  • Tyrosine Kinase Inhibitors
  • Heterodimerization Inhibitors
  • STAT-3 Inhibitors
  • Cyclin-Dependent Kinase Inhibitors
  • Apoptosis Inducers
  • Hypoxia Inducible Factor-1 Pathway
  • Dipeptidyl Peptidase Inhibitors
  • Small Molecule Therapies for Cancer Cachexia
  • Small Molecule Immunostimulatory Agents
  • Small Molecule Adhesion Targets
  • Small Molecule Inhibitors: Resistance Mechanisms
  • New Chemical Entities - Standard Chemotherapy Approaches
  • New Investigative and Experimental Oncology Products
  • Novel Oncology Products: Nontargeted Experimental and Investigational Agents
  • Novel Drug Delivery Approaches in Research and Development
  • Novel Molecular Tumour Targets in Research and Development
  • Antisense Therapeutics
  • Novel Treatment Approaches in Early Preclinical Stages of Development
  • General Experimental Approaches
  • Chemopreventive Approaches
  • Development Outlook for Investigative/Experimental Oncology Products
  • General Considerations
  • Comparison of Therapeutic Treatment Modalities
  • Standard Chemotherapy
  • Small Molecule Inhibitors
  • Monoclonal Antibodies
  • Therapeutic Vaccines
  • Novel Treatment Delivery Approaches
  • Antisense Technologies
• Chapter 7. Companies Developing Cancer Drugs
  • Leading Companies and Oncology Pipelines
  • Leading Multinational Companies and Oncology Products
  • Roche/Genentech
  • Novartis
  • Sanofi-Aventis
  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Pfizer
  • Bristol-Myers Squibb
  • Schering-Plough
  • Johnson & Johnson
  • Other Oncology Focused Multinationals with Promising Pipelines
  • Abbott Laboratories/TAP Pharmaceutical
  • Merck & Co.
  • Takeda
  • Wyeth
  • Leading Biopharmaceutical Companies and Oncology Therapeutics
  • Amgen
  • Genentech
  • Genzyme
  • Serono
  • Medimmune
  • Chiron
  • Millennium Pharmaceuticals
  • Specialty Oncology Drug Discovery and Development Companies
  • Antigenics
  • Antisoma
  • Celgene
  • Cell Therapeutics
  • Ecopia Pharmaceutical Company
  • Helix Biopharma
  • ImClone Systems
  • Immunogen
  • Immusol
  • Inovio
  • Kosan Biosciences
  • MediGene
  • Milagen
  • MorphoSys
  • Myriad Pharmaceuticals
  • NeoRx
  • Protherics
  • Receptor Biologix
  • Regeneron Pharmaceuticals
  • Starpharma
  • Syrrx
  • U3 Pharma
  • Vertex Pharmaceuticals
  • Viventia Biotech
  • Xoma
  • Zymo Genetics
  • Other Discovery and Development Companies Specializing in Oncology Therapeutics
  • Reference Sources
• List of Tables
  • Table 1.1 Highest Mortality Rates for Common Cancers
  • Table 1.2 Common Cancers in the United Kingdom Relative to Gender, 2004
  • Table 1.3 Incidence Trends for the Common Cancers in the United Kingdom (1990-2001)
  • Table 1.4 Mortality Rates in the United Kingdom, 2003
  • Table 1.5 Changes in 5- and 10-Year Survival Rates for Common Cancers, United Kingdom (1971-1999 Diagnosis)
  • Table 1.6 Incidence Rates for Common Cancers in the United States and United Kingdom
  • Table 1.7 Incidence and Mortality for Most Prevalent Cancer in the United States, 2005 Estimates for Men and Women
  • Table 1.8 Trends in Cancer Incidence, 2005 (% Total New Cases)
  • Table 1.9 Incidence, Mortality, Survival Trends, and Risk Factors for 10 Less Common Cancers in the United States
  • Table 1.10 Chemotherapy Options for Common Solid Tumour Malignancies by Disease Stage
  • Table 2.1 Viruses Implicated in Human Cancers
  • Table 2.2 Genes Most Commonly Identified in Human Cancers
  • Table 2.3 Genes Most Commonly Implicated in Major Human Cancers
  • Table 2.4 Chemotherapy Drugs Most Commonly Used to Treat Cancer
  • Table 3.1 General Staging Criteria Relevant to Chemotherapy Treatment Options in Solid Tumour Malignancies
  • Table 3.2 Chemotherapy Drugs Most Commonly Used to Treat Lung Cancer
  • Table 3.3 Most Common Treatment Options for Limited Small Cell Lung Carcinoma
  • Table 3.4 Most Common Treatment Options for Extensive Small Cell Lung Carcinoma
  • Table 3.5 Less Common Treatment Protocols for Extensive Small Cell Lung Carcinoma
  • Table 3.6 Most Common Treatment Protocols for Nonsmall Cell Lung Carcinoma
  • Table 3.7 Experimental Chemotherapy for Advanced Lung Cancer
  • Table 3.8 Chemotherapy Drugs Most Commonly Used to Treat Colorectal Cancer
  • Table 3.9 Breast Cancer Chemotherapy Treatment Options
  • Table 3.10 Hormonal Therapies Used in the Treatment of Advanced Prostate Cancer
  • Table 3.11 Chemotherapy Drugs Most Commonly Used to Treat Ovarian Cancer
  • Table 3.12 Second-Line Treatments for Ovarian Cancer
  • Table 3.13 First-Line Combined Treatment Options for Advanced Ovarian Cancer
  • Table 3.14 Second-Line Combined Treatment Options for Resistant Ovarian Cancer
  • Table 3.15 Combined Chemotherapy Treatment Protocols for Acute Myeloid Leukaemia
  • Table 3.16 Common Drugs Used to Treat Chronic Myeloid Leukaemia
  • Table 3.17 Standard Treatment Options for Chronic Lymphocytic Leukaemia
  • Table 3.18 Standard Treatment Options for Hodgkin's Disease
  • Table 3.19 Treatment Options for Advanced Low-Grade Non-Hodgkin's Lymphoma
  • Table 3.20 Treatment Options for Early-Stage Fast-Growing Non-Hodgkin's Lymphoma
  • Table 3.21 Chemotherapy Drugs Approved by the United States Food and Drug Administration
  • Table 3.22 Drugs Administered to Combat Dose-Limiting Side Effects of Chemotherapy
  • Table 4.1 Estimated Global Sales (US$) and Forecasts of Leading Cancer Chemo-therapies, 2005-2016
  • Table 4.2 Approximate 2004 Expenditures for Chemotherapy Treatment of the Most Common Cancers Based on Incidence Rates
  • Table 4.3 Comparative Assessment of Positive Outcomes and Problems in Healthcare Systems, United States/United Kingdom
  • Table 4.4 Accessibilty Ratings to New Cancer Drugs in Europe by Country
  • Table 4.5 Global Incidence and Mortality Ratios for the Most Common Cancers by Gender
  • Table 4.6 Global Incidence of Cancer by Site, Males and Females
  • Table 4.7 Estimated Percentage of Cancer Cases by Type in Men and Women, United States, 2005
  • Table 4.8 Predicted Average Lifetime Risk for Developing Cancer in Men and Women, 1999-2001 Estimates
  • Table 4.9 Five-Year Relative Survival Rates for the Most Common Cancers, United States, 1995-2000
  • Table 4.10 Comparison of 5-Year Survival Rates (%) for Most Common Cancers over Three Time Periods, United States
  • Table 4.11 Death Rates from the Most Common Cancers in Men and Women, United States, 2005 Estimates
  • Table 4.12 New Anticancer Drugs with Strong Commercial Outlook Based on Clinical Efficacy
  • Table 5.1 New Drug Application Submissions (Oncology), United States Food and Drug Administration, 2005
  • Table 5.2 Comparison of Angiogenesis Inhibitors
  • Table 5.3 Major Projected Competitors: Oncology Drugs for Advanced Colon Cancer that Target Growth Factor Signal Pathways
  • Table 5.4 Tykerb: Summary of Clinical Trial Studies
  • Table 5.5 Late-Stage Oncology Products in Clinical Development Grouped by Mechanism of Action
  • Table 5.6 GlaxoSmithKline's Portfolio of Oncology Products in Research and Development
  • Table 5.7 Histone Deacetylase Inhibitors in Clinical Trials, 2006
  • Table 5.8 Biotechnological Oncology Products in Clinical Development by Clinical Phase
  • Table 5.9 Top Prospects for Market Success in the Oncology Pipeline
  • Table 6.1 United States Federal Drug Administration Approved and Investigational Monoclonal Antibody Therapeutics for Cancer
  • Table 6.2 Small Molecule Cancer Therapeutics in Research and Development by Clinical Phase
  • Table 6.3 Novel Druggable Tumour Targets in Research and Development
  • Table 6.4 Antisense Therapeutics in Research and Development
  • Table 7.1 The Top 50 Global Pharmaceutical Companies (2004 and 2005 Revenues)
  • Table 7.2 Global Portfolio Revenues and Market Share of Cancer Chemotherapies, 2005 (US$m)
  • Table 7.3 Roche`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
  • Table 7.4 Novartis` Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
  • Table 7.5 Sanofi-Aventis` Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
  • Table 7.6 AstraZeneca`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
  • Table 7.7 Eli Lilly's Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
  • Table 7.8 GlaxoSmithKline`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
  • Table 7.9 Pfizer`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
  • Table 7.10 Bristol-Myers Squibb`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
  • Table 7.11 Schering-Plough`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
  • Table 7.12 Johnson & Johnson`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
  • Table 7.13 Amgen`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
  • Table 7.14 Genentech`s Key Chemotherapy Portfolio and Product Sales, 2005 (US$m)
  • Table 7.15 Additional Discovery and Development Companies Specializing in Oncology Therapeutics
• List of Figures
  • Figure 1.1 Total Cancer Mortality (Age Standardized Rates)
  • Figure 1.2 Total Cancer Incidence (Age Standardized Rates)
  • Figure 1.3 Averaged Incidence of the Most Common Cancers in the United Kingdom for Men and Women
  • Figure 1.4 Incidence and Mortality of the 10 Most Common Cancers in the United States, 2005 Estimates
  • Figure 1.5 Lung Cancer Incidence (Age Standardized Rates)
  • Figure 1.6 Colon Cancer Incidence (Age Standardized Rates)
  • Figure 1.7 Breast Cancer Incidence/Mortality (Age Standardized Rates)
  • Figure 1.8 Prostate Cancer Incidence/Mortality (Age Standardized Rates)
  • Figure 1.9 Bladder Cancer Incidence (Age Standardized Rates)
  • Figure 1.10 Stomach Cancer Incidence (Age Standardized Rates)
  • Figure 1.11 Cervical Cancer Incidence/Mortality (Age Standardized Rates)
  • Figure 1.12 Melanoma Incidence (Age Standardized Rates)
  • Figure 1.13 Larynx Cancer Incidence (Age Standardized Rates)
  • Figure 1.14 Hodgkin's Disease Incidence (Age Standardized Rates)
  • Figure 1.15 Non-Hodgkin's Lymphoma Incidence (Age Standardized Rates)
  • Figure 1.16 Ovarian Cancer Incidence/Mortality (Age Standardized Rates)
  • Figure 1.17 Chemotherapy Regimens Used to Treat Non-Hodgkin's Lymphoma
  • Figure 2.1 Origins of Chemotherapy Resistance
  • Figure 2.2 Pharmacological Parameters of Drug Resistance
  • Figure 2.3 Proliferative Cell Cycle: Genes and Drug Targets
  • Figure 3.1 Factors Associated with Successful Chemotherapy Outcome
  • Figure 4.1 Best-Selling Chemotherapies, 2005 (US$m)
  • Figure 4.2 Market Share of the Top 10 Cancer Chemotherapies, 2005 & 2010
  • Figure 4.3 Growth Rates of Best-Selling Cancer Chemotherapy Drugs, 2005
  • Figure 4.4 Total Healthcare Costs: % Gross Domestic Product (GDP) by Country (2002)
  • Figure 4.5 Key Parameters of Cancer Drug Market
  • Figure 5.1 Therapeutic Classes of Oncology Drugs in the Product Pipeline
  • Figure 6.1 General Clinical Research Areas in Cancer Therapeutics
  • Figure 6.2 General Categories of Therapeutic Enhancement Approaches
  • Figure 6.3 Biotechnology Approaches to Cancer Therapeutic Research and Development
  • Figure 6.4 Types of Therapeutic Cancer Vaccines in Clinical Research and Development
  • Figure 6.5 Tumour Antigen Targets Used in the Development of Therapeutic Cancer Vaccines
  • Figure 6.6 Monoclonal Antibody Therapeutic Targets
  • Figure 6.7 Small Molecule Therapy Targets
  • Figure 6.8 Combined Chemotherapy Treatment Possibilities
  • Figure 6.9 Cell Targets of Experimental Cancer Therapeutics: Drugs and Delivery Mode
  • Figure 7.1 Leading Oncology Companies by Chemotherapy Portfolio Revenues, 2005 (US$m)

Related products

Top 7 Cancer Indications Therapeutic & Competitive Insights With our 750 page report entitled "Top 7 Cancer Indications - Therapeutic & Competitive Insights" we present one of the largest reports published evaluating therapeutic and competitive insights in the...

Commercializing Peptides in Oncology A Decision Support Tool for Optimizing the Pipeline This report comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. The report extensively analyses 125...

Stakeholder Opinions: Sarcomas Introduction Sarcomas are a diverse group of rare connective tissue tumors that are categorized as soft tissue sarcomas or bone sarcomas. Although sarcomas represent only 1% of all adult and...

Global Market for Antimicrobials and Antifungals; The Challenging Resistance to 2016 Antibiotic resistance is a significant problem which is negatively impacting prescribing patterns, consequently reducing antibiotic usage. The total worldwide market for antibiotics and antifungals was US$25 billion in 2005, but...

North American Advanced 3D/4D Visualization and Clinical Applications for Medical Imaging Markets This research service provides a study of the North American market for advanced (3D/4D) visualization and clinical applications in medical imaging. The study prevents historical, base year and forecast market...

Breast Cancer Therapeutic And Competitive Insights Introduction Overall approximately 3 million women in the US are living with breast cancer. But, even with an increasing incidence, the mortality rate has dropped slightly during the last 10-15 years....

U.S. Biopharmaceutical Market rends, Forecast, Competition & Strategic Analysis (2009 - 2016) This research report analyzes the U.S. biopharmaceuticals market and its growth factors, with special emphasis on the top companies in the field and their product pipeline. While it looks at...

Triple Positive Metastatic Breast Cancer Clinical Insights from a US Oncologists Survey Patient specific case scenario that unfold throughout the report, presented to 174 high-prescribing oncologists on Triple Positive Metastatic Breast Cancer for their open responses on clinical decisions.  Patient progression reveals: Decisions...

European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) The European market for gastrointestinal endoscopic devices was valued at more than €793 million in 2009. These devices include: GI endoscopes Capsule endoscopy devices Stenting devices Dilation balloons Endoscopic retrograde...

Hong Kong SMBG Devices and Strips Market This Market Engineering research service has been developed to address the dynamics of blood glucose monitoring device sales and consumption of test strips in Hong Kong. The market is divided...

Triple Negative Metastatic Breast Cancer Clinical Insights from a US Oncologists Survey Patient specific case scenario that unfold throughout the report, presented to 174 high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their open responses on clinical decisions.  Patient progression reveals: Decisions...

European Markets for Peripheral Vascular Devices (15 Countries) In 2009, the European market for peripheral vascular devices was valued at €677.5 million. European Markets for Peripheral Vascular Devices 2010 covers Austria Benelux France Germany Italy Portugal Scandinavia Switzerland the United Kingdom The markets covered in this...

European Cancer Support Therapies Market This research service analyses the European cancer support therapies market. The base year is 2009 with forecasts running through 2016. The segments covered include: the European bisphosphonates market, European growth...

European Markets for Wound and Tissue Management 2011 In 2009, the total European wound and tissue management markets were valued at nearly €2.3 billion. The European markets for wound and tissue management covers 15 countries in Europe including...

U.S. Market for Medical Imaging Equipment 2010 In 2009, the U.S. market for medical imaging equipment was valued at over $8.5 billion, a decrease of 14.6% over 2008. The U.S. Market for Medical Imaging ...

Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) – Developmental Therapeutics Review Q4 2010 Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) - Developmental Therapeutics Review - Q4 2010 Summary Global Market Direct's pharmaceuticals report, "Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) - Developmental Therapeutics Review -...

Global Cancer Focus Company Directory Global Cancer Focus Company Directory pulls out virtually all cancer drug developing companies in the world. After several acquisitions and mergers in the market place, BioSeeker offers you the tool...

Stakeholder Insight: Supportive Care in Cancer Treatment Some first-generation products proving difficult to dislodge Introduction Supportive care is used to prevent or treat the adverse effects that arise as a result of cancer treatment, particularly chemotherapy. While newer molecular targeted therapies do not exist without...

Lung Cancer Therapeutics Market Outlook and Pipeline Analysis With over 50% of all non-small cell lung cancer (NSCLC) patients diagnosed at the advanced stages of the disease, and 95% of all small-cell lung cancer (SCLC) patients unsuitable for surgical resection, drug...

Cancer Therapies: Technologies and Global Markets Study Objectives Bcc's Goal In Conducting This Study Is To Provide An Overview Of The Current And Potential Aspects Of The Global Market For Cancer Therapies. The Report Determines The Market...

Optimizing Treatment for Metastatic Breast Cancers US Oncologist Survey A survey of 175 U.S. oncologists who manage 15 or more patients with metastatic breast cancer monthly responded to a survey in which they were presented with 4 patient case...

Cancer Supportive Care Products Market to 2016 Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars Summary GBI Research, the leading business intelligence provider, has...

Cancer Therapeutics: The Worldwide Market The Worldwide Market , 2nd Editon This completely updated edition of this comprehensive and indispensable report covers the breadth of traditional IVD testing. The report contains complete market statistics and analysis for all areas of IVD,...

BSD Medical Corporation Product Pipeline Analysis BSD Medical Corporation Product Pipeline Analysis Summary This report is an insightful source for data, analysis and strategic insights into a Scope's pipeline and investigational products. The report also provides details on...

European Markets for Vascular Access Devices and Accessories 2010 (15 Countries) In 2009, the European market for vascular access devices and accessories was valued at €902.4 million. This market includes: Implantable ports, Huber needles, Central venous catheters (CVCs), Dialysis catheters, Peripherally inserted central...

European Market for Orthopedic Trauma Devices (15 Countries) 2010 The mean age in most European countries is increasing and as a result, bone fractures are increasing in prevalence. This trend is driving the market for orthopedic trauma bone fixation...

View all products in this category